

ASX Release

SUDA ANNOUNCES STRONG REVENUE GROWTH FOR WESTCOAST SUBSIDIARY

PERTH, AUSTRALIA – 27 February 2017: SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, announces today that its wholly owned subsidiary Westcoast Surgical & Medical Supplies (“Westcoast”) reported strong revenue growth in January 2017.

Westcoast generated revenue of \$714k for the month of January 2017, an increase of approximately 70% from January 2016 and 36% higher than the average month in the 2017 financial year to-date.

Westcoast has recently been awarded several new contracts, including the supply of medical products to oil rigs and ships. Whilst there was a one-off boost to revenue in January 2017, Westcoast anticipates ongoing revenue streams from these new contracts and from other contracts that are in negotiation.

Mr Stephen Carter, SUDA’s Managing Director & CEO, commented: “We are delighted by the progress of our subsidiary, Westcoast. The company is successfully winning higher-margin business to supply products to new clients based on its strong track record of excellent customer service. With positive cash flow and strong growth trajectory, Westcoast is a valuable asset within the SUDA group.”



**Further information:
STEPHEN CARTER
CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR
SUDA LTD**

Tel: +61 8 6142 5555

sjcarter@sudaltd.com.au

NOTES TO EDITORS:

About SUDA LTD

SUDA LTD (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (ie: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes Zolpimist™, a first-in-class oral spray of zolpidem for insomnia. Zolpimist™ is marketed in the USA and SUDA has rights to the product outside of North America. SUDA's most advanced development-stage product, ArTiMist®, is a novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist® was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction and pre-procedural anxiety. For more information, visit www.sudaltd.com.au

About Westcoast Surgical & Medical Supplies

Westcoast Surgical & Medical Supplies (Westcoast) is a sales and logistics organisation distributing healthcare consumables and capital equipment, primarily in the West Australian marketplace. It was established as a family business in 1995. SUDA Ltd acquired the business in 2006. Westcoast operates as a distributor in a standard industry model and services the Hospital, Aged Care, Mining Operations and the diverse allied health areas amongst others. For more information, visit www.westcoastsurgical.com.au or phone +61 8 9455 6676.